Cortland Associates Inc. MO Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Cortland Associates Inc. MO lowered its position in shares of Danaher Co. (NYSE:DHR) by 1.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 171,882 shares of the conglomerate’s stock after selling 1,841 shares during the period. Danaher comprises about 4.5% of Cortland Associates Inc. MO’s portfolio, making the stock its 9th biggest position. Cortland Associates Inc. MO’s holdings in Danaher were worth $39,455,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its position in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. lifted its stake in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the period. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Danaher in the 4th quarter valued at about $74,551,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $223.12 on Thursday. The stock has a fifty day simple moving average of $236.09 and a two-hundred day simple moving average of $253.66. Danaher Co. has a 1-year low of $223.00 and a 1-year high of $281.70. The firm has a market cap of $161.15 billion, a price-to-earnings ratio of 42.58, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter last year, the business earned $2.09 earnings per share. Analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.48%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DHR. Barclays dropped their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus upped their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $284.14.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.